These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33207902)

  • 21. Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis.
    Becciolini A; Parisi S; Caccavale R; Bravi E; Lumetti F; Andracco R; Volpe A; Gardelli L; Girelli F; Di Donato E; Santilli D; Lucchini G; Ditto MC; Platè I; Arrigoni E; Mozzani F; Riva M; Marchetta A; Fusaro E; Sandri G; Salvarani C; Paroli M; Ariani A
    J Pers Med; 2022 Feb; 12(3):. PubMed ID: 35330335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?
    Roccuzzo G; Rozzo G; Burzi L; Repetto F; Dapavo P; Ribero S; Quaglino P
    Dermatol Ther; 2022 Nov; 35(11):e15803. PubMed ID: 36062429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting.
    Deprez N; De Somer T; Baert D; Deceuninck M; Huys I; Mattens V; Sterckx A; Vanderstraeten E; Vandervoort J; Van Heddegem N; Dewint P
    Acta Gastroenterol Belg; 2022; 85(4):557-564. PubMed ID: 36566364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease.
    Hanauer S
    Immunotherapy; 2022 Dec; 14(17):1353-1359. PubMed ID: 36511191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PF-06410293: An Adalimumab Biosimilar.
    Lee A; Shirley M
    BioDrugs; 2020 Oct; 34(5):695-698. PubMed ID: 32949384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABP 501 for the treatment of rheumatoid arthritis.
    Pelechas E; Voulgari PV; Drosos AA
    Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients.
    Brouwer R; Ten Klooster PM; Masselink JB; Vonkeman HE
    Pharmacol Res Perspect; 2022 Dec; 10(6):e01025. PubMed ID: 36479936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5.
    Bouhnik Y; Carbonnel F; Fumery M; Flamant M; Buisson A; Camoin A; Addison J
    Dig Liver Dis; 2023 Dec; 55(12):1658-1666. PubMed ID: 37308394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
    McConachie S; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
    Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases.
    Mathew AJ; Ganapati A; T SK; Goel R; P S; Danda D
    J Assoc Physicians India; 2017 May; 65(5 Suppl):30-32. PubMed ID: 28836749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS).
    Young D; Harris C; Rahmany S; Iria I; Gonçalves J; Addison J; Harvey J; Latter S; Cummings F
    Int J Clin Pharm; 2024 Oct; 46(5):1091-1101. PubMed ID: 38734866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients' satisfaction: a cross-sectional survey by patient organisations.
    Kaneko K; Prieto-Alhambra D; Jacklin C; Bosworth A; Dickinson S; Berry S; McAteer H; Taylor PC
    BMJ Open; 2022 Feb; 12(2):e050949. PubMed ID: 35172995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
    Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
    Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease].
    Navas-López VM; Pujol Muncunill G; Llerena E; Navalón Rubio M; Gil-Ortega D; Varea-Calderón V; Sierra Salinas C; Martin-de-Carpi J
    An Pediatr (Engl Ed); 2018 Feb; 88(2):89-99. PubMed ID: 28434894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBest.
    Kirsten N; Ohm F; Gehrdau K; Girbig G; Stephan B; Ben-Anaya N; Pinter A; Bechara FG; Presser D; Zouboulis CC; Augustin M
    Life (Basel); 2022 Sep; 12(10):. PubMed ID: 36294953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.